vs
Empire State Realty Trust, Inc.（ESRT）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
Empire State Realty Trust, Inc.的季度营收约是VERACYTE, INC.的1.4倍（$190.3M vs $139.1M），VERACYTE, INC.净利率更高（20.6% vs 1.6%，领先19.1%），VERACYTE, INC.同比增速更快（21.5% vs 5.7%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 0.2%）
帝国州房地产信托是一家美国房地产投资信托企业，持有并运营纽约大都会区的优质办公、零售及住宅物业，旗下资产包括地标性建筑帝国大厦，主打可持续运营模式，服务各类租户及住户，专注实现长期资产增值。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
ESRT vs VCYT — 直观对比
营收规模更大
ESRT
是对方的1.4倍
$139.1M
营收增速更快
VCYT
高出15.8%
5.7%
净利率更高
VCYT
高出19.1%
1.6%
两年增速更快
VCYT
近两年复合增速
0.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $190.3M | $139.1M |
| 净利润 | $3.0M | $28.7M |
| 毛利率 | — | 72.7% |
| 营业利润率 | 15.5% | 16.3% |
| 净利率 | 1.6% | 20.6% |
| 营收同比 | 5.7% | 21.5% |
| 净利润同比 | -73.7% | — |
| 每股收益（稀释后） | $0.20 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESRTVCYT
| Q1 26 | $190.3M | $139.1M | ||
| Q4 25 | $199.2M | $140.6M | ||
| Q3 25 | $197.7M | $131.9M | ||
| Q2 25 | $191.3M | $130.2M | ||
| Q1 25 | $180.1M | $114.5M | ||
| Q4 24 | $197.6M | $118.6M | ||
| Q3 24 | $199.6M | $115.9M | ||
| Q2 24 | $189.5M | $114.4M |
净利润ESRTVCYT
| Q1 26 | $3.0M | $28.7M | ||
| Q4 25 | $32.2M | $41.1M | ||
| Q3 25 | $13.6M | $19.1M | ||
| Q2 25 | $11.4M | $-980.0K | ||
| Q1 25 | $15.8M | $7.0M | ||
| Q4 24 | $18.8M | $5.1M | ||
| Q3 24 | $22.8M | $15.2M | ||
| Q2 24 | $28.6M | $5.7M |
毛利率ESRTVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% |
营业利润率ESRTVCYT
| Q1 26 | 15.5% | 16.3% | ||
| Q4 25 | 17.8% | 26.4% | ||
| Q3 25 | 19.9% | 17.4% | ||
| Q2 25 | 18.4% | -4.0% | ||
| Q1 25 | 14.3% | 2.5% | ||
| Q4 24 | 21.7% | 3.5% | ||
| Q3 24 | 22.7% | 10.4% | ||
| Q2 24 | 20.8% | 4.0% |
净利率ESRTVCYT
| Q1 26 | 1.6% | 20.6% | ||
| Q4 25 | 16.1% | 29.3% | ||
| Q3 25 | 6.9% | 14.5% | ||
| Q2 25 | 6.0% | -0.8% | ||
| Q1 25 | 8.8% | 6.2% | ||
| Q4 24 | 9.5% | 4.3% | ||
| Q3 24 | 11.4% | 13.1% | ||
| Q2 24 | 15.1% | 5.0% |
每股收益（稀释后）ESRTVCYT
| Q1 26 | $0.20 | $0.35 | ||
| Q4 25 | $0.11 | $0.50 | ||
| Q3 25 | $0.05 | $0.24 | ||
| Q2 25 | $0.04 | $-0.01 | ||
| Q1 25 | $0.05 | $0.09 | ||
| Q4 24 | $0.07 | $0.07 | ||
| Q3 24 | $0.08 | $0.19 | ||
| Q2 24 | $0.10 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.8M | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $1.3B |
| 总资产 | $4.4B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESRTVCYT
| Q1 26 | $68.8M | $439.1M | ||
| Q4 25 | $132.7M | $362.6M | ||
| Q3 25 | $154.1M | $315.6M | ||
| Q2 25 | $94.6M | $219.5M | ||
| Q1 25 | $187.8M | $186.1M | ||
| Q4 24 | $385.5M | $239.1M | ||
| Q3 24 | $421.9M | $274.1M | ||
| Q2 24 | $535.5M | $235.9M |
股东权益ESRTVCYT
| Q1 26 | $1.8B | $1.3B | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.0B | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $1.0B | $1.1B |
总资产ESRTVCYT
| Q1 26 | $4.4B | $1.4B | ||
| Q4 25 | $4.5B | $1.4B | ||
| Q3 25 | $4.1B | $1.4B | ||
| Q2 25 | $4.1B | $1.3B | ||
| Q1 25 | $4.1B | $1.3B | ||
| Q4 24 | $4.5B | $1.3B | ||
| Q3 24 | $4.4B | $1.3B | ||
| Q2 24 | $4.4B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $35.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 10.0% | — |
| 现金转化率经营现金流/净利润 | — | 1.23× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESRTVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $249.1M | $52.6M | ||
| Q3 25 | $105.3M | $44.8M | ||
| Q2 25 | $26.7M | $33.6M | ||
| Q1 25 | $83.1M | $5.4M | ||
| Q4 24 | $260.9M | $24.5M | ||
| Q3 24 | $102.8M | $30.0M | ||
| Q2 24 | $37.1M | $29.6M |
自由现金流ESRTVCYT
| Q1 26 | — | — | ||
| Q4 25 | $50.6M | $48.8M | ||
| Q3 25 | $72.8M | $42.0M | ||
| Q2 25 | $-55.1M | $32.3M | ||
| Q1 25 | $41.1M | $3.5M | ||
| Q4 24 | $88.0M | $20.4M | ||
| Q3 24 | $-65.1M | $27.7M | ||
| Q2 24 | $19.5M | $26.8M |
自由现金流率ESRTVCYT
| Q1 26 | — | — | ||
| Q4 25 | 25.4% | 34.7% | ||
| Q3 25 | 36.8% | 31.8% | ||
| Q2 25 | -28.8% | 24.8% | ||
| Q1 25 | 22.8% | 3.1% | ||
| Q4 24 | 44.5% | 17.2% | ||
| Q3 24 | -32.6% | 23.9% | ||
| Q2 24 | 10.3% | 23.4% |
资本支出强度ESRTVCYT
| Q1 26 | 10.0% | — | ||
| Q4 25 | 99.6% | 2.7% | ||
| Q3 25 | 16.5% | 2.1% | ||
| Q2 25 | 42.8% | 1.0% | ||
| Q1 25 | 23.4% | 1.6% | ||
| Q4 24 | 87.5% | 3.5% | ||
| Q3 24 | 84.1% | 1.9% | ||
| Q2 24 | 9.3% | 2.4% |
现金转化率ESRTVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | 7.74× | 1.28× | ||
| Q3 25 | 7.72× | 2.34× | ||
| Q2 25 | 2.35× | — | ||
| Q1 25 | 5.27× | 0.76× | ||
| Q4 24 | 13.88× | 4.80× | ||
| Q3 24 | 4.51× | 1.98× | ||
| Q2 24 | 1.30× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESRT
| Rental revenue (1) | $166.1M | 87% |
| Observatory revenue | $18.5M | 10% |
| Other revenue and fees | $4.1M | 2% |
| Lease termination fees | $1.4M | 1% |
| Third-party management and other fees | $277.0K | 0% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
